TY - JOUR T1 - Model-based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans JF - medRxiv DO - 10.1101/2020.05.09.20096586 SP - 2020.05.09.20096586 AU - Can Liu AU - Vivaswath S. Ayyar AU - Xirong Zheng AU - Wenbo Chen AU - Songmao Zheng AU - Hardik Mody AU - Weirong Wang AU - Donald Heald AU - Aman P. Singh AU - Yanguang Cao Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/13/2020.05.09.20096586.abstract N2 - Chimeric antigen receptor (CAR)-T cell therapy has achieved considerable success in treating B- cell hematologic malignancies. However, the challenges of extending CAR-T therapy to other tumor types, particularly solid tumors, remain appreciable. There are substantial variabilities in CAR-T cellular kinetics across CAR-designs, CAR-T products, dosing regimens, patient responses, disease types, tumor burdens, and lymphodepletion conditions. As a “living drug”, CAR-T cellular kinetics typically exhibit four distinct phases: distribution, expansion, contraction, and persistence. The cellular kinetics of CAR-T may correlate with patient responses, but which factors determine CAR-T cellular kinetics remain poorly defined. Herein, we developed a cellular kinetic model to retrospectively characterize CAR-T kinetics in 218 patients from 7 trials and systematically compared CAR-T kinetics across patient populations and tumor types. Based on our analysis results, CAR-T cells exhibited a significantly higher cell proliferation rate constant and capacity but a lower contraction rate constant in patients who responded to treatment. CAR-T cells proliferate at a higher rate constant in hematologic malignancies than in solid tumors. Within the assessed dose ranges (107-109 cells), CAR-T doses were weakly correlated with CAR-T cellular kinetics and patient response status, suggesting steep dose-response curves. In conclusion, the developed CAR-T cellular kinetic model adequately characterized the multiphasic CAR-T cellular kinetics and supported systematic evaluations of the potentially influencing factors, which can have significant implications for the development of more effective CAR-T therapies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIt is a meta-analysis of multiple trial's dataFunding StatementNational Institute of Health (GM119661) and Janssen R&DAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data analyzed in this manuscript was from the published literature, which were all cited in the manuscript. ER -